Panic Disorder Market Report and Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,499	180 Pages	Expert Market Research	February, 2024	EMAR18558267

Best Price Guarantee
Price	from $5,499
Length	180 Pages
Publisher	Expert Market Research
Published Date	February, 2024
SKU	EMAR18558267

Panic Disorder Market Report and Forecast 2024-2032

Panic Disorder Market Report and Forecast 2024-2032

Panic Disorder Market Outlook

The panic disorder market size was valued at USD 9.7 billion in 2023, driven by growing recognition of mental health disorders in the major markets. The market size is anticipated to grow at a CAGR of 4.18 % during the forecast period of 2024-2032 to achieve a value of USD 14 billion by 2032.

Panic Disorder: Introduction

Panic Disorder is a mental health condition characterized by sudden, intense episodes of fear or discomfort known as panic attacks. These attacks can include symptoms like heart palpitations, sweating, trembling, and feelings of impending doom. Individuals may worry excessively about future attacks and avoid situations they associate with panic. The exact cause is unknown, but factors like genetics, stress, and changes in brain function may contribute. Treatment typically involves therapy, medication, or a combination of both.

Key Trends in the Panic Disorder Market

There's a growing recognition of mental health disorders, including panic disorder, leading to earlier diagnosis and treatment. Public health campaigns and educational programs are reducing stigma and encouraging individuals to seek help.

The market is seeing innovation in treatment methods, including the development of new pharmacological treatments with fewer side effects. Personalized medicine is becoming more prevalent, tailoring treatments to individual genetic profiles and symptoms.

Digital health solutions, like mobile apps for anxiety management and telepsychiatry services, are on the rise. These technologies offer remote monitoring, therapy, and support, making treatment more accessible and convenient.

There's an increasing interest in holistic approaches, including mindfulness, yoga, and dietary changes, often used alongside conventional treatments. This trend reflects a broader shift towards comprehensive, patient-centered care.

CBT remains a cornerstone in the treatment of panic disorder, with ongoing research and development of new, more effective therapy models. There's a trend towards integrating CBT with other therapies and adapting it for diverse populations and settings.

Panic Disorder Market Segmentation

Market Breakup by Type

Agoraphobia
Social Anxiety Disorder (SAD)
Obsessive-Compulsive Disorder (OCD)
Bipolar Disorder
Post-Traumatic Stress Disorder (PTSD)
Specific Phobias, Generalized Anxiety Disorder (GAD)
Major Depressive Disorder (MDD)
Others

Market Breakup by Therapy

Electroconvulsive Therapy ECT
Cognitive-Behavioral Therapy (CBT)

Market Breakup by Drug Class

Benzodiazepines (BZD)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Monoamine Oxidase Inhibitors (MAOIs)
Anti-Depressants
Tricyclic Antidepressants (TCAs)
Pregabalin
Buspirone
Sertraline
Others

Market Breakup by Route of Administration

Oral
Parenteral

Market Breakup by Region

United States
EU-4 and the United Kingdom
Germany
France
Italy
Spain
United Kingdom
Japan

Panic Disorder Market Overview

In North America, the panic disorder market is influenced by a high prevalence of anxiety disorders and a growing awareness of mental health issues. The region has a well-established healthcare infrastructure with widespread access to mental health services. There's a significant emphasis on therapy and counseling, along with a robust market for psychiatric medications. Public health initiatives and private organizations actively promote mental health education and support, contributing to the market's dynamics.

Europe's market is marked by comprehensive healthcare systems and strong mental health policies. There's a focus on early diagnosis and treatment, with countries like the UK, Germany, and France leading in mental health research and services. The region shows a preference for psychotherapy and holistic treatment approaches, alongside traditional medication. EU regulations and initiatives aimed at reducing the stigma around mental health further shape the market, encouraging individuals to seek treatment.

Japan market is evolving, driven by changing attitudes towards mental health and improving healthcare infrastructure. It is experiencing increased recognition of panic disorder and other mental health conditions. However, cultural attitudes and limited access to mental health services in some areas pose challenges. The region shows potential growth in the pharmaceutical sector and a gradual increase in mental health awareness and services.

Panic Disorder Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd.
Mylan
AstraZeneca
Abbott
Baxter
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Recordati S.p.A.
Boehringer Ingelheim International GmbH.
Neurocrine Biosciences, Inc
Recordati S.p.A.
Sanofi

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.

1 Preface: 1.1 Objectives of the Study; 1.2 Key Assumptions; 1.3 Report Coverage – Key Segmentation and Scope; 1.4 Research Methodology
2 Executive Summary
3 Panic Disorder Overview: 3.1 Guidelines and Stages; 3.2 Pathophysiology; 3.3 Screening and Diagnosis; 3.4 Treatment Pathway
4 Patient Profile: 4.1 Patient Profile Overview; 4.2 Patient Psychology and Emotional Impact Factors; 4.3 Risk Assessment and Treatment Success Rate
5 Panic Disorder Epidemiology Analysis – 7MM: 5.1 7MM Epidemiology Scenario Overview (2017-2032); 5.2 United States Panic Disorder Epidemiology Forecast (2017-2032); 5.3 EU-4 and United Kingdom Panic Disorder Epidemiology Forecast (2017-2032); 5.3.1 Germany Panic Disorder Epidemiology Forecast (2017-2032); 5.3.2 France Panic Disorder Epidemiology Forecast (2017-2032); 5.3.3 Italy Panic Disorder Epidemiology Forecast (2017-2032); 5.3.4 Spain Panic Disorder Epidemiology Forecast (2017-2032); 5.3.5 United Kingdom Panic Disorder Epidemiology Forecast (2017-2032); 5.4 Japan Panic Disorder Epidemiology Forecast (2017-2032)
6 Panic Disorder Market Overview – 7MM: 6.1 Panic Disorder Market Historical Value (2017-2023); 6.2 Panic Disorder Market Forecast Value (2024-2032)
7 Panic Disorder Market Landscape – 7MM: 7.1 Panic Disorder Developers Landscape; 7.1.1 Analysis by Year of Establishment; 7.1.2 Analysis by Company Size; 7.1.3 Analysis by Region; 7.2 Panic Disorder Product Landscape; 7.2.1 Analysis by Diseases Type; 7.2.2 Analysis by Drug Class; 7.2.3 Analysis by Route of Administration
8 Panic Disorder Challenges and Unmet Needs: 8.1 Treatment Pathway Challenges; 8.2 Compliance and Drop-Out Analysis; 8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Panic Disorder Market Dynamics: 10.1 Market Drivers and Constraints; 10.2 SWOT Analysis; 10.3 Porter’s Five Forces Model; 10.4 Key Demand Indicators; 10.5 Key Price Indicators; 10.6 Industry Events, Initiatives, and Trends; 10.7 Value Chain Analysis
11 Panic Disorder Market Segmentation – 7MM: 11.1 Panic Disorder Market by Type; 11.1.1 Market Overview; 11.1.2 Agoraphobia; 11.1.3 Social Anxiety Disorder (SAD); 11.1.4 Obsessive-Compulsive Disorder (OCD); 11.1.5 Bipolar Disorder; 11.1.6 Post-Traumatic Stress Disorder (PTSD); 11.1.7 Specific Phobias, Generalized Anxiety Disorder (GAD); 11.1.8 Major Depressive Disorder (MDD); 11.1.9 Others; 11.2 Panic Disorder Market by Therapy; 11.2.1 Market Overview; 11.2.2 Electroconvulsive Therapy ECT; 11.2.3 Cognitive-Behavioral Therapy (CBT); 11.3 Panic Disorder Market by Drug Class; 11.3.1 Market Overview; 11.3.2 Benzodiazepines (BZD); 11.3.3 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); 11.3.4 Monoamine Oxidase Inhibitors (MAOIs); 11.3.5 Anti-Depressants; 11.3.6 Tricyclic Antidepressants (TCAs); 11.3.7 Pregabalin; 11.3.8 Buspirone; 11.3.9 Sertraline; 11.3.10 Others; 11.4 Panic Disorder Market by Route of Administration; 11.4.1 Market Overview; 11.4.2 Oral; 11.4.3 Parenteral; 11.5 Panic Disorder Market by Region; 11.5.1 Market Overview; 11.5.2 United States; 11.5.3 EU-4 and the United Kingdom; 11.5.3.1 Germany; 11.5.3.2 France; 11.5.3.3 Italy; 11.5.3.4 Spain; 11.5.3.5 United Kingdom; 11.5.4 Japan
12 United States Panic Disorder Market: 12.1 Panic Disorder Market Historical Value (2017-2023); 12.2 Panic Disorder Market Forecast Value (2024-2032); 12.3 Panic Disorder Market by Disease Type; 12.4 Panic Disorder Market by Treatment Type
13 EU-4 and United Kingdom Panic Disorder Market: 13.1 Panic Disorder Market Historical Value (2017-2023); 13.2 Panic Disorder Market Forecast Value (2024-2032); 13.3 Germany Panic Disorder Market Overview; 13.3.1 Panic Disorder Market by Disease Type; 13.3.2 Panic Disorder Market by Treatment Type; 13.4 France Panic Disorder Market Overview; 13.4.1 Panic Disorder Market by Disease Type; 13.4.2 Panic Disorder Market by Treatment Type; 13.5 Italy Panic Disorder Market Overview; 13.5.1 Panic Disorder Market by Disease Type; 13.5.2 Panic Disorder Market by Treatment Type; 13.6 Spain Panic Disorder Market Overview; 13.6.1 Panic Disorder Market by Disease Type; 13.6.2 Panic Disorder Market by Treatment Type; 13.7 United Kingdom Panic Disorder Market Overview; 13.7.1 Panic Disorder Market by Disease Type; 13.8 Panic Disorder Market by Treatment Type
14 Japan Panic Disorder Market: 14.1 Panic Disorder Market Historical Value (2017-2023); 14.2 Panic Disorder Market Forecast Value (2024-2032); 14.3 Panic Disorder Market by Disease Type; 14.4 Panic Disorder Market by Treatment Type
15 Patent Analysis: 15.1 Analysis by Type of Patent; 15.2 Analysis by Publication year; 15.3 Analysis by Issuing Authority; 15.4 Analysis by Patent Age; 15.5 Analysis by CPC Analysis; 15.6 Analysis by Patent Valuation; 15.7 Analysis by Key Players
16 Grants Analysis: 16.1 Analysis by year; 16.2 Analysis by Amount Awarded; 16.3 Analysis by Issuing Authority; 16.4 Analysis by Grant Application; 16.5 Analysis by Funding Institute; 16.6 Analysis by NIH Departments; 16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis: 17.1 Analysis by Trial Registration Year; 17.2 Analysis by Trial Status; 17.3 Analysis by Trial Phase; 17.4 Analysis by Therapeutic Area; 17.5 Analysis by Geography
18 Funding Analysis: 18.1 Analysis by Funding Instances; 18.2 Analysis by Type of Funding; 18.3 Analysis by Funding Amount; 18.4 Analysis by Leading Players; 18.5 Analysis by Leading Investors; 18.6 Analysis by Geography
19 Partnership and Collaborations Analysis: 19.1 Analysis by Partnership Instances; 19.2 Analysis by Type of Partnership; 19.3 Analysis by Leading Players; 19.4 Analysis by Geography
20 Supplier Landscape: 20.1 Teva Pharmaceutical Industries Ltd; 20.1.1 Financial Analysis; 20.1.2 Product Portfolio; 20.1.3 Demographic Reach and Achievements; 20.1.4 Mergers and Acquisition; 20.1.5 Certifications; 20.2 Sun Pharmaceutical Industries Ltd.; 20.2.1 Financial Analysis; 20.2.2 Product Portfolio; 20.2.3 Demographic Reach and Achievements; 20.2.4 Mergers and Acquisition; 20.2.5 Certifications; 20.3 Mylan; 20.3.1 Financial Analysis; 20.3.2 Product Portfolio; 20.3.3 Demographic Reach and Achievements; 20.3.4 Mergers and Acquisition; 20.3.5 Certifications; 20.4 AstraZeneca; 20.4.1 Financial Analysis; 20.4.2 Product Portfolio; 20.4.3 Demographic Reach and Achievements; 20.4.4 Mergers and Acquisition; 20.4.5 Certifications; 20.5 Abbott; 20.5.1 Financial Analysis; 20.5.2 Product Portfolio; 20.5.3 Demographic Reach and Achievements; 20.5.4 Mergers and Acquisition; 20.5.5 Certifications; 20.5.6 BaxterFinancial Analysis; 20.5.7 Product Portfolio; 20.5.8 Demographic Reach and Achievements; 20.5.9 Mergers and Acquisition; 20.5.10 Certifications; 20.6 Baxter; 20.6.1 Financial Analysis; 20.6.2 Product Portfolio; 20.6.3 Demographic Reach and Achievements; 20.6.4 Mergers and Acquisition; 20.6.5 Certifications; 20.7 Bristol-Myers Squibb Company; 20.7.1 Financial Analysis; 20.7.2 Product Portfolio; 20.7.3 Demographic Reach and Achievements; 20.7.4 Mergers and Acquisition; 20.7.5 Certifications; 20.8 Eli Lilly and Company; 20.8.1 Financial Analysis; 20.8.2 Product Portfolio; 20.8.3 Demographic Reach and Achievements; 20.8.4 Mergers and Acquisition; 20.8.5 Certifications; 20.9 F. Hoffmann-La Roche Ltd; 20.9.1 Financial Analysis; 20.9.2 Product Portfolio; 20.9.3 Demographic Reach and Achievements; 20.9.4 Mergers and Acquisition; 20.9.5 Certifications; 20.10 GlaxoSmithKline plc; 20.10.1 Financial Analysis; 20.10.2 Product Portfolio; 20.10.3 Demographic Reach and Achievements; 20.10.4 Mergers and Acquisition; 20.10.5 Certifications; 20.11 Recordati S.p.A.; 20.11.1 Financial Analysis; 20.11.2 Product Portfolio; 20.11.3 Demographic Reach and Achievements; 20.11.4 Mergers and Acquisition; 20.11.5 Certifications; 20.12 Boehringer Ingelheim International GmbH.; 20.12.1 Financial Analysis; 20.12.2 Product Portfolio; 20.12.3 Demographic Reach and Achievements; 20.12.4 Mergers and Acquisition; 20.12.5 Certifications; 20.13 Neurocrine Biosciences, Inc; 20.13.1 Financial Analysis; 20.13.2 Product Portfolio; 20.13.3 Demographic Reach and Achievements; 20.13.4 Mergers and Acquisition; 20.13.5 Certifications; 20.14 Recordati S.p.A.; 20.14.1 Financial Analysis; 20.14.2 Product Portfolio; 20.14.3 Demographic Reach and Achievements; 20.14.4 Mergers and Acquisition; 20.14.5 Certifications; 20.15 Sanofi; 20.15.1 Financial Analysis; 20.15.2 Product Portfolio; 20.15.3 Demographic Reach and Achievements; 20.15.4 Mergers and Acquisition; 20.15.5 Certifications
21 Panic Disorders Market - Distribution Model (Additional Insight): 21.1 Overview; 21.2 Potential Distributors; 21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight): 23.1 Very Small Companies; 23.2 Small Companies; 23.3 Mid-Sized Companies; 23.4 Large Companies; 23.5 Very Large Companies
24 Payment Methods (Additional Insight): 24.1 Government Funded; 24.2 Private Insurance; 24.3 Out-of-Pocket; *Additional insights provided are customisable as per client requirements.